CVS Health Q3 revenue $89.8B (+10.6%), GAAP EPS $1.75, Adj EPS $2.21, FY GAAP EPS guidance revised to $6.37-$6.61

CVS HEALTH Corp

2023-Q3 EPS reported $4.88 revenue$263,963,000,000

Total revenues $89.8B, up 10.6% YoY; GAAP diluted EPS $1.75 vs loss of $2.59 prior year.
Adjusted EPS $2.21 vs $2.17 prior year; YTD cash flow from operations $16.1B.
FY GAAP EPS guidance revised to $6.37-$6.61 from $6.53-$6.75; adjusted EPS guidance confirmed at $8.50-$8.70.
Launched Cordavis to commercialize biosimilars; Aetna's 2024 Medicare offerings expanded.
Appointed Scott Kirby (United Airlines CEO) and Michael Mahoney (Boston Scientific CEO) to board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVS HEALTH Corp reported three months ended September 30, 2023 results: revenue $89.8 billion, EPS GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21. Guidance reaffirmed.

Period: three months ended September 30, 2023
Revenue: $89.8 billion
EPS: GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(NYSE: CVS) today announced operating results for the three months ended September 30, 2023. Third quarter highlights Key financial data • Total revenues increased to $89.8 billion, up 10.6% compared to prior year • GAAP diluted EPS of $1.75 and Adjusted EPS of $2.21 Year-to-date highlights • Total revenues increased to $264.0 billion, up 10.6% compared to

View on SEC.gov

Browse all earnings releases →

CVS HEALTH Corp filing history →

Source: SEC EDGAR

accession 0000064803-23-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.